Current CV risk scores overestimate risk in elderly and underestimate risk in young subjects. Prof. Frank Visseren emphasizes the need of CV lifetime risk prediction and presents the U-prevent calculator that estimates gain in CVD-free life based on lifetime CV risk and treatment effects in individuals.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

ESC 2018 Dr. Dorresteijn presents how the lifetime risk model U-prevent can estimate the effect of preventive treatment and explains the value of this model in shared decision-making.

Download the meeting impression of this PACE symposium during ESC 2018, which reviewed PCSK9 inhibition with regard to science, outcomes and guidance.

ESC 2018 Biomarkers play an important role in CV risk prediction. Nina Paynter, PhD, presents the definition of a good biomarker and explains how deep learning can improve CV risk assessment.

ESC 2018 Women are still underrepresented in CV clinical trials. Dr. Jeanine Roeters van Lennep explains why sex-specific analyses are important in research into efficacy and safety of CV medication.

ESC 2018 Nicole Jaspers, MD, presents a model that predicts lifetime risk of CV events in individuals without CVD, including lifetime benefit of therapy, which allows shared-decision making in daily practice.

Prof. Jorge Plutzky explains BET inhibition as a novel therapeutic strategy for controlling pathologic cardiovascular responses.

Prof. Kastelein discusses whether LDL-c eradication makes more sense than LDL-c lowering, based on the latest scientific insights.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

ESC 2018 Prof. dr. Pieter Vandervoort, Jean-Paul Vendeville and Gijs Berkelmans discuss how digital health can help us screening for atrial fibrillation in general population by using a smartphone.